News

Cyclophosphamide Is Safest When It's Infused


 

Dr. Douglas J. Veale of University College Dublin, who was involved in FAST, offered a closing comment.

“I think you would agree that if we thought 10 years ago that we would be sitting in a room this big talking to this many people about any drug trial in systemic sclerosis, we would have been very excited. I think to have two trials showing benefits for patients is a remarkable achievement. The greatest need now is close collaboration from both sides of the Atlantic in designing similar studies with sufficient power,” he said.

“I could not possibly agree more,” Dr. Furst replied.

Pages

Recommended Reading

'Second Hits' Trigger Problems In Antiphospholipid Syndrome
MDedge Rheumatology
Systemic Vasculitides: Treatment Myths and Pearls
MDedge Rheumatology
Vessel Size Matters in Diagnosis of Vasculitis
MDedge Rheumatology
Inflammatory Eye Diseases Call for Careful, Individualized Treatment to Maintain Vision
MDedge Rheumatology
Roux-en-Y Bypass Aids Esophageal Scleroderma
MDedge Rheumatology
Image of the Month
MDedge Rheumatology
Yearly PAH Screening in Scleroderma Is Crucial
MDedge Rheumatology
Sixth Drug for Pulmonary Artery Hypertension Gets FDA Nod
MDedge Rheumatology
IVIG Is Safe, Effective for Scleromyxedema Lesions
MDedge Rheumatology
Statins Aid Vasculopathy, Stymie Ulcers in Sclerosis : Raynaud's patients treated with atorvastatin had less pain and fewer ulcers than controls.
MDedge Rheumatology